Stock Price Quote

IPCA LABORATORIES LTD.

NSE : IPCALABBSE : 524494ISIN CODE : INE571A01038Industry : Pharmaceuticals & DrugsHouse : Ipca Laboratories
BSE1194.20-20 (-1.65 %)
PREV CLOSE ( ) 1214.20
OPEN PRICE ( ) 1240.40
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 12340
TODAY'S LOW / HIGH ( )1190.55 1240.40
52 WK LOW / HIGH ( )670 1264
NSE1194.85-19.65 (-1.62 %)
PREV CLOSE( ) 1214.50
OPEN PRICE ( ) 1215.00
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 1194.85 (164)
VOLUME 212369
TODAY'S LOW / HIGH( ) 1190.60 1224.70
52 WK LOW / HIGH ( )669.8 1263.95
1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 19-10 1949
Management Info
Premchand Godha - Chairman Pranay Godha - Managing Director
Registered Office

Address 48 , Kandivli Industrial Estate,Kandivli (West), ,
Mumbai,
Maharashtra-400067

Phone 022- 66474444 / 62106050

Email investors@ipca.com

Website www.ipca.com

Registrars Details
Link Intime India Pvt Ltd.
C 101, 247 Park,LBS Marg,Vikhroli (West),Mumbai
Listing : BSE, NSE, MCX

NEWS

27Feb IPCA Laboratories informs about postal
IPCA Laboratories has informed that the Company has on 26ht February, 20..
27Feb Ipca Laboratories informs about press
Ipca Laboratories has informed that it enclosed notice published in the..
23Feb Ipca Laboratories informs about notice
Ipca Laboratories has informed that it enclosed Postal Ballot Notice (No..
16Feb Ipca Laboratories informs about audio
Pursuant to Regulation 30 of the Securities and Exchange Board of India..
25Jan lpca Laboratories informs about loss o
Pursuant to Regulation 39(3) of the Securities and Exchange Board of Ind..

Financials

in Millions
QTR Dec 23 ANNUAL 23
Net Profit1369.45057
Gross Profit 2001.5 7504.9
Operating Profit 2903.810230.4
Net Sales 15068.358146.2

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Abbott India (BSE)
peergroup  28639.35 (0.55%)
M.Cap ( in Cr)60755.26
Bharat Parenterals (BSE)
peergroup  1147.65 (10.28%)
M.Cap ( in Cr)667.89
Astrazeneca Pharma I (BSE)
peergroup  5567.65 (1.95%)
M.Cap ( in Cr)13915.75
Neuland Laboratories (BSE)
peergroup  7063.75 (1.37%)
M.Cap ( in Cr)9039.30
Mankind Pharma (BSE)
peergroup  2097.55 (1.58%)
M.Cap ( in Cr)84123.57

Shareholding Pattern

NON-INSTITUTION 8.92%
PROMOTERS 46.29%
FI/BANKS/INSURANCE 4.54%
MUTUAL FUNDS/UTI 29.25%
GOVERNMENT 0%
FII 0%

About Ipca Laboratories Ltd.

Ipca Laboratories Ltd. was incorporated in the year 1949. Its today's share price is 1194.2. Its current market capitalisation stands at Rs 30332.88 Cr. In the latest quarter, company has reported Gross Sales of Rs. 58146.2 Cr and Total Income of Rs.59120.6 Cr. The company's management includes Narendra Mairpady, Kamal Kishore Seth, Manisha Premnath, Anand T Kusre, Prashant Godha, Pranay Godha, Ajit Kumar Jain, Premchand Godha, Harish P Kamath.

It is listed on the BSE with a BSE Code of 524494 , NSE with an NSE Symbol of IPCALAB and ISIN of INE571A01038. It's Registered office is at 48 , Kandivli Industrial Estate,Kandivli (West), Mumbai-400067, Maharashtra. Their Registrars are K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.) It's auditors are GM Kapadia & Co, Natvarlal Vepari & Co

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.